PMID- 15977971
OWN - NLM
STAT- MEDLINE
DCOM- 20060727
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 65
IP  - 10
DP  - 2005
TI  - Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in 
      acid-related disorders.
PG  - 1419-26
AB  - Lansoprazole is an H+, K+-adenosine triphosphatase proton pump inhibitor (PPI) 
      used for management of acid-related disorders. Lansoprazole has been reformulated 
      as an oro-dispersible tablet (LODT) that quickly dissolves in the mouth without 
      water. In healthy adults the safety and bioavailability of LODT 15-30 mg, taken 
      without water or dispersed in water, were found to be comparable with those of 
      lansoprazole 15-30 mg capsules. Moreover, the bioavailability of LODT 
      administered without water has been found to be similar to that of 
      water-dispersed LODT given via a nasogastric tube. In a clinical study, the vast 
      majority of patients found the mouth feel of LODT acceptable and almost all found 
      it easy to take. A comparison of LODT with esomeprazole in a small group of 
      patients with non-erosive reflux disease showed similar decreases in symptoms 
      from baseline and no significant difference between groups. In conclusion, LODT 
      is effective, bioequivalent to the capsule formulation and acceptable to 
      patients. LODT offers an alternative dose administration method to all patients 
      requiring a PPI, especially those who have difficulty swallowing, and may 
      increase patient convenience and compliance.
FAU - Baldi, Fabio
AU  - Baldi F
AD  - Department of Gastroenterology, S. Orsola Malpighi Hospital, Bologna, Italy. 
      baldi@med.unibo.it
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Tablets)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - N3PA6559FT (Esomeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Anti-Ulcer Agents/pharmacokinetics/*therapeutic use
MH  - Esomeprazole/*analogs & derivatives/blood/pharmacokinetics/therapeutic use
MH  - Gastroesophageal Reflux/*drug therapy
MH  - Humans
MH  - Lansoprazole
MH  - Proton Pump Inhibitors
MH  - Tablets
MH  - Technology, Pharmaceutical/methods/trends
MH  - Treatment Outcome
RF  - 33
EDAT- 2005/06/28 09:00
MHDA- 2006/07/28 09:00
CRDT- 2005/06/28 09:00
PHST- 2005/06/28 09:00 [pubmed]
PHST- 2006/07/28 09:00 [medline]
PHST- 2005/06/28 09:00 [entrez]
AID - 65107 [pii]
AID - 10.2165/00003495-200565100-00007 [doi]
PST - ppublish
SO  - Drugs. 2005;65(10):1419-26. doi: 10.2165/00003495-200565100-00007.